author-photo

Wendy De Roock

Katholieke Universiteit Leuven

20

Papers

3756

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy

2014 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (41)
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

2014 Journal of Cancer Research and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (28)
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

2013 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (92)
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.

2013 Clinical Colorectal Cancer
Show All
- Source
- Cite
- Save
Citations (15)
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype

2013 Biomarkers
Show All
- Source
- Cite
- Save
Citations (16)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

2011 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (464)
KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab—Reply

2011 JAMA
Show All
- Source
- Cite
- Save
Citations (12)
Intrinsic Resistance To the Antiproliferative Effects of Azd6244 a Selective Mek1/2 Inhibitor Is Associated With Concomitant K-ras and Pi3kca Gene Mutations in Colorectal Cancer Cells

2010 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

2010 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (1640)
Reply to C. Cremolini et al

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)